StroMel™ (Planned)
Osteoarthritis (other joints)
Key Facts
About Akan Biosciences
Akan Biosciences is a private, pre-revenue biotech founded in 2018 and headquartered in Frederick, Maryland, USA. The company is developing a portfolio of adipose-derived stem cell therapies targeting a broad range of inflammatory and degenerative conditions, including osteoarthritis, wound healing, Crohn's disease, and autism. Its lead candidate, StroMel™, is in Phase 2 for knee osteoarthritis, positioning the company in the competitive but high-potential cell and gene therapy sector.
View full company profileAbout Akan Biosciences
Akan Biosciences is a private, pre-revenue biotech founded in 2018 and headquartered in Frederick, Maryland, USA. The company is developing a portfolio of adipose-derived stem cell therapies targeting a broad range of inflammatory and degenerative conditions, including osteoarthritis, wound healing, Crohn's disease, and autism. Its lead candidate, StroMel™, is in Phase 2 for knee osteoarthritis, positioning the company in the competitive but high-potential cell and gene therapy sector.
View full company profileAbout Akan Biosciences
Akan Biosciences is a private, pre-revenue biotech founded in 2018 and headquartered in Frederick, Maryland, USA. The company is developing a portfolio of adipose-derived stem cell therapies targeting a broad range of inflammatory and degenerative conditions, including osteoarthritis, wound healing, Crohn's disease, and autism. Its lead candidate, StroMel™, is in Phase 2 for knee osteoarthritis, positioning the company in the competitive but high-potential cell and gene therapy sector.
View full company profileAbout Akan Biosciences
Akan Biosciences is a private, pre-revenue biotech founded in 2018 and headquartered in Frederick, Maryland, USA. The company is developing a portfolio of adipose-derived stem cell therapies targeting a broad range of inflammatory and degenerative conditions, including osteoarthritis, wound healing, Crohn's disease, and autism. Its lead candidate, StroMel™, is in Phase 2 for knee osteoarthritis, positioning the company in the competitive but high-potential cell and gene therapy sector.
View full company profileAbout Akan Biosciences
Akan Biosciences is a private, pre-revenue biotech founded in 2018 and headquartered in Frederick, Maryland, USA. The company is developing a portfolio of adipose-derived stem cell therapies targeting a broad range of inflammatory and degenerative conditions, including osteoarthritis, wound healing, Crohn's disease, and autism. Its lead candidate, StroMel™, is in Phase 2 for knee osteoarthritis, positioning the company in the competitive but high-potential cell and gene therapy sector.
View full company profile